Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.27−0.01 (-3.26%)
Close on Nov 18, 2026Market cap $51.83MP/E –Yield –
Heron Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Heron Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$10.86M, down 981.8% year over year. For fiscal 2025 it was -$2.54M. The highest annual figure on record is -$2.54M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.54M | – |
| FY2024 | Dec 31, 2024 | -$11.53M | – |
| FY2023 | Dec 31, 2023 | -$110.62M | – |
| FY2022 | Dec 31, 2022 | -$174.66M | – |
| FY2021 | Dec 31, 2021 | -$217.83M | – |
| FY2020 | Dec 31, 2020 | -$228.16M | – |
| FY2019 | Dec 31, 2019 | -$210.69M | – |
| FY2018 | Dec 31, 2018 | -$183.94M | – |
| FY2017 | Dec 31, 2017 | -$194.56M | – |
| FY2016 | Dec 31, 2016 | -$170.92M | – |
| FY2015 | Dec 31, 2015 | -$96.93M | – |
| FY2014 | Dec 31, 2014 | -$74.56M | – |
| FY2013 | Dec 31, 2013 | -$54.46M | – |
| FY2012 | Dec 31, 2012 | -$23.83M | – |
| FY2011 | Dec 31, 2011 | -$11.06M | – |
| FY2010 | Dec 31, 2010 | -$9.93M | – |
| FY2009 | Dec 31, 2009 | -$10.24M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.04M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.77M | -251.1% |
| Q4 FY2025 | Dec 31, 2025 | $38.00K | -99.1% |
| Q3 FY2025 | Sep 30, 2025 | -$4.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.64M | – |
| Q1 FY2025 | Mar 31, 2025 | $3.15M | – |
| Q4 FY2024 | Dec 31, 2024 | $4.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.45M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.22M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.40M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.06M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$41.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$49.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$62.92M | – |
| Q4 FY2021 | Dec 31, 2021 | -$53.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$51.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$60.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$52.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$61.30M | – |
| Q3 FY2020 | Sep 30, 2020 | -$58.38M | – |
| Q2 FY2020 | Jun 30, 2020 | -$55.75M | – |
| Q1 FY2020 | Mar 31, 2020 | -$52.73M | – |
| Q4 FY2019 | Dec 31, 2019 | -$59.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -$34.85M | – |
| Q2 FY2019 | Jun 30, 2019 | -$51.78M | – |
| Q1 FY2019 | Mar 31, 2019 | -$64.70M | – |
| Q4 FY2018 | Dec 31, 2018 | -$51.31M | – |
| Q3 FY2018 | Sep 30, 2018 | -$41.78M | – |
| Q2 FY2018 | Jun 30, 2018 | -$38.85M | – |
| Q1 FY2018 | Mar 31, 2018 | -$51.99M | – |
| Q4 FY2017 | Dec 31, 2017 | -$61.89M | – |
| Q3 FY2017 | Sep 30, 2017 | -$41.31M | – |
| Q2 FY2017 | Jun 30, 2017 | -$42.06M | – |
| Q1 FY2017 | Mar 31, 2017 | -$49.30M | – |
| Q4 FY2016 | Dec 31, 2016 | -$46.80M | – |
| Q3 FY2016 | Sep 30, 2016 | -$47.73M | – |
See a number that looks wrong?